RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Novo Nordisk, a diabetes-focused multinational pharma, has launched INNOVO, a platform designed to promote China innovation by connecting Novo Nordisk with China academic institutions, bio-tech startups and incubators. The company aims to accelerate its scientific research though the relationships. Novo Nordisk has a long history in China. It set up a China office in 1994 and established an R&D center in Beijing in 1997, the first multinational biopharma to do so. The Novo Nordisk Research Center in China will be in charge of running INNOVO.
Source: China Biotoday
